2023 Department of Medicine Grand Rounds | Human Herpesvirus 6 (HHV 6) in Hematopoietic Cell Transplantation (HCT) and Immune Effector Cells (IEC): Controversies in Surveillance and Management
Allogeneic Hematopoietic Cell Transplantation (HCT) patients and those who undergo CAR T Cell therapy are at high risk for infectious complications, including Human Herpesvirus 6 (HHV6). Even though up to 40% of allogeneic HCT patients may reactivate HHV6 within the first 1-3 months after allogeneic HCT, there is lack of data in determining the role of surveillance and pre-emptive treatment of HHV6 viremia. This is particularly the case in CAR T, where we do not have good data on reactivation rates or disease incidence.
Since the major complication of encephalitis from HHV6 is very infrequent despite high reactivation rates, it is unclear who will develop this disease even if they have viral reactivation. There is a lack of large RCT's and evidence is limited to small open-label clinical trials and heterogeneity in treatments for hematologic malignancies leading to HCT. It is imperative to stay abreast on the controversies in surveillance and management of this disease.
All physicians and HCT and Infectious Disease APP's.
- Demonstrate knowledge on when to treat Human Herpes Virus 6 (HHV6) infection.
- Outline various HHV6 syndromes and approaches to evaluation and management.
- Identify risk factors for severe HHV6 infection.
- Identify limitations of preemptive antiviral therapy for asymptomatic HHV6 viremia.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Joshua Hill, MD Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington
Presenter: Dr. Hill has indicated the following financial relationship: Consultant for AlloVir.
Planner: Sanjeet Dadwal, MD has indicated the following financial relationships: Consultant for AlloVir, Merck, and Takeda; Grant/Research Support from AlloVir, Ansun, Karius, and Merck; On the Speakers Bureau for Astellas, Merck, and Takeda; Other financial/material interest (onetime speaking engagement) from Viracor.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer with no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2023 Department of Medicine Grand Rounds | Human Herpesvirus 6 (HHV 6) in Hematopoietic Cell Transplantation (HCT) and Immune Effector Cells (IEC): Controversies in Surveillance and Management for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance